Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingyi No. 2 granule is a traditional Chinese medicine (TCM) formulation developed by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is specifically indicated for the treatment of hemorrhagic fever with renal syndrome (HFRS), also known as epidemic hemorrhagic fever, during the febrile (fever) period. The granule is typically administered as an adjunct to standard Western medical treatments to prevent the progression of the disease into more severe or critical stages. As a botanical product, its therapeutic effect is derived from a combination of herbal ingredients intended to modulate the host immune response and manage systemic symptoms associated with hantavirus infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingyi No. 2 granule.